Xuelin Huang

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint A frailty model for informative censoring
    Xuelin Huang
    Department of Biostatistics, University of Michigan, Ann Arbor 48109 2029, USA
    Biometrics 58:510-20. 2002
  2. ncbi request reprint Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Biometrics 62:901-9. 2006
  3. pmc Regression survival analysis with an assumed copula for dependent censoring: a sensitivity analysis approach
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 64:1090-9. 2008
  4. pmc Accuracy of RNA-Seq and its dependence on sequencing depth
    Guoshuai Cai
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Bioinformatics 13:S5. 2012
  5. pmc Analysis of multi-stage treatments for recurrent diseases
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Stat Med 31:2805-21. 2012
  6. pmc Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:3123-7. 2012
  7. ncbi request reprint A parallel phase I/II clinical trial design for combination therapies
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 63:429-36. 2007
  8. ncbi request reprint A joint frailty model for survival and gap times between recurrent events
    Xuelin Huang
    Anderson Cancer Center, Department of Biostatistics, The University of Texas, M D 1515 Holcombe Boulevard, Unit 447, Houston, Texas 77030, USA
    Biometrics 63:389-97. 2007
  9. ncbi request reprint A test for informative censoring in clustered survival data
    Xuelin Huang
    Department of Biostatistics, M D Anderson Cancer Center, The University of Texas, Houston 77030, USA
    Stat Med 23:2089-107. 2004
  10. doi request reprint A multistate model for bivariate interval-censored failure time data
    Richard J Cook
    Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
    Biometrics 64:1100-9. 2008

Collaborators

Detail Information

Publications73

  1. ncbi request reprint A frailty model for informative censoring
    Xuelin Huang
    Department of Biostatistics, University of Michigan, Ann Arbor 48109 2029, USA
    Biometrics 58:510-20. 2002
    ..Simulation studies and analysis of data for kidney disease patients are provided. Consequences of incorrectly assuming noninformative censoring are investigated...
  2. ncbi request reprint Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Biometrics 62:901-9. 2006
    ..The methods are illustrated by a retrospective study of patients with soft tissue sarcoma, which motivated this research...
  3. pmc Regression survival analysis with an assumed copula for dependent censoring: a sensitivity analysis approach
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 64:1090-9. 2008
    ..We apply the proposed sensitivity analysis approach to the data from an AIDS clinical trial in which 27% of the patients withdrew due to toxicity or at the request of the patient or investigator...
  4. pmc Accuracy of RNA-Seq and its dependence on sequencing depth
    Guoshuai Cai
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Bioinformatics 13:S5. 2012
    ..RNA-Seq is becoming a common technique for surveying gene expression based on DNA sequencing. As it is not clear how increased sequencing capacity has affected measurement accuracy of mRNA, we sought to investigate that relationship...
  5. pmc Analysis of multi-stage treatments for recurrent diseases
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Stat Med 31:2805-21. 2012
    ..We evaluated the proposed model and estimation method by simulation studies and illustrated using the motivating, real data set that describes initial and salvage treatments for patients with soft tissue sarcoma...
  6. pmc Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:3123-7. 2012
    ..The objective of this report was to estimate the increasing prevalence and plateau prevalence of CML in future years...
  7. ncbi request reprint A parallel phase I/II clinical trial design for combination therapies
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 63:429-36. 2007
    ..The simulations show that the proposed design saves sample size, has better power, and efficiently assigns more patients to doses with higher efficacy levels...
  8. ncbi request reprint A joint frailty model for survival and gap times between recurrent events
    Xuelin Huang
    Anderson Cancer Center, Department of Biostatistics, The University of Texas, M D 1515 Holcombe Boulevard, Unit 447, Houston, Texas 77030, USA
    Biometrics 63:389-97. 2007
    ..The method is evaluated by simulation studies and illustrated through a study of patients with heart failure. Sensitivity analysis for the parametric assumption of the frailty distribution is assessed by simulations...
  9. ncbi request reprint A test for informative censoring in clustered survival data
    Xuelin Huang
    Department of Biostatistics, M D Anderson Cancer Center, The University of Texas, Houston 77030, USA
    Stat Med 23:2089-107. 2004
    ..Simulation studies show that the proposed test works well under various scenarios. For illustration, the test is applied to a data set for kidney disease patients from multiple dialysis centres...
  10. doi request reprint A multistate model for bivariate interval-censored failure time data
    Richard J Cook
    Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
    Biometrics 64:1100-9. 2008
    ..The method is illustrated by application to data from a trial of HIV patients where the events are the onset of viral shedding in the blood and urine among individuals infected with cytomegalovirus...
  11. pmc Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
    Aziz Nazha
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Am J Hematol 88:961-6. 2013
    ..In multivariate analysis, CIA retained its favorable impact on OS compared to IA. Thus, CIA is an effective and safe therapy for patients ≤60 years with newly diagnosed AML...
  12. pmc Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:1214-21. 2013
    ..2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR...
  13. pmc Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:4471-7. 2012
    ..Standard therapy for older patients with acute myeloid leukemia (AML) has a poor outcome. The authors have designed a combination of clofarabine plus low-dose cytarabine followed by a prolonged consolidation alternating with decitabine...
  14. pmc Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:244-51. 2012
    ..The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies...
  15. pmc Clofarabine combinations as acute myeloid leukemia salvage therapy
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2090-6. 2008
    ..Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine...
  16. pmc Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease
    Daniel A Anaya
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 1402, USA
    Cancer 112:2030-7. 2008
    ..However, to the authors' knowledge, the role of this treatment in selected patients with early stage III disease has not been well studied...
  17. pmc Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
    Hagop Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1981-7. 2012
    ..Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML...
  18. pmc Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1133-7. 2007
    ..The comparative efficacy of these 2 forms of treatment in MDS is unknown. The objective of the current study was to compare the efficacy and toxicity profiles of decitabine and intensive chemotherapy in MDS...
  19. pmc Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Gautam Borthakur
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:73-8. 2010
    ..Complete remission was achieved in 2 of 6 minimally pre-treated patients. We conclude that the combination of azacitidine and cytarabine is feasible but has limited activity in relapsed/refractory AML...
  20. pmc A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1638-45. 2008
    ..4 months vs 5.8 months; P = .1). Clofarabine plus low-dose cytarabine has a higher response rate than clofarabine alone with comparable toxicity. This trial is registered at www.clinicaltrials.gov as no. NCT00088218...
  21. pmc Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  22. pmc Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
    Yiming Chen
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:2507-13. 2011
    ....
  23. pmc Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
    Farhad Ravandi
    Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 172:392-400. 2016
    ..Achievement of an MRD negative state assessed by MFC is an important predictor of DFS and OS in adult patients with ALL. ..
  24. pmc Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome
    Tapan M Kadia
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 157:312-20. 2012
    ..Infusion reactions occurred in about half the patients and were manageable. Myelosuppression, elevation in liver enzymes, and infections were common. The early mortality in MDS patients was 13% vs. 0% in AA patients...
  25. pmc Using short-term response information to facilitate adaptive randomization for survival clinical trials
    Xuelin Huang
    Department of Biostatistics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, U S A
    Stat Med 28:1680-9. 2009
    ..The new design uses fewer patients, and can more effectively assign patients to the better treatment arms. We demonstrate these properties through simulation studies...
  26. pmc DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes
    Lanlan Shen
    Department of Leukemia and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:605-13. 2010
    ..Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we investigated the association between DNA methylation and clinical outcome in MDS...
  27. doi request reprint Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
    Naveen Pemmaraju
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas
    Am J Hematol . 2017
    ..Prospective studies of long-term MRD assessments, together with less toxic treatment strategies to eradicate MRD, are warranted. This article is protected by copyright. All rights reserved...
  28. doi request reprint Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
    Tapan M Kadia
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 121:2375-82. 2015
    ..The treatment of older adults with acute myeloid leukemia (AML) using standard intensive chemotherapy has been associated with poor outcomes. Effective, less toxic therapies are needed to achieve and maintain durable remissions...
  29. ncbi request reprint Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  30. pmc Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis
    Sergej Konoplev
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:4737-44. 2009
    ..Nucleophosmin (NPM1) gene mutations are reported to predict a favorable prognosis in acute myeloid leukemia (AML) patients. Aberrant cytoplasmic localization of nucleophosmin (NPM) protein is reported be a surrogate for NPM1 gene mutation...
  31. ncbi request reprint Shared frailty models for recurrent events and a terminal event
    Lei Liu
    Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109 2029, USA
    Biometrics 60:747-56. 2004
    ..This model avoids the difficulties encountered in alternative approaches which attempt to specify a dependent joint distribution with marginal proportional hazards and yields an estimate of the degree of dependence...
  32. ncbi request reprint Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  33. pmc Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer . 2016
    ..Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management. Posttreatment prognostic factors are increasingly being evaluated...
  34. doi request reprint Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia
    Nicholas J Short
    Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas
    Am J Hematol 91:385-9. 2016
    ..ACCR was not associated with adverse outcomes in ALL and did not add additional prognostic information when MRD status by MFC was known...
  35. pmc Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
    Elias Jabbour
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 16:1547-55. 2015
    ..We examined the activity and safety of combining chemotherapy with ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia in this continuing phase 2 trial...
  36. pmc Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 121:4158-64. 2015
    ..The long-term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is not well established...
  37. pmc Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome
    Talha Badar
    Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Am J Hematol 90:769-73. 2015
    ..7 and 72 months respectively (P = 0.33). BMN is not a rare entity in AML and ALL, but is infrequent. BMN in AML and in ALL is suggestive of inferior response and poor prognosis...
  38. doi request reprint Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
    Elias Jabbour
    Department of Leukemia, U T M D Anderson Cancer Center, Houston, Texas
    Am J Hematol 90:193-6. 2015
    ..5, and 2.4 months, respectively. Our current analyses identified a subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted...
  39. pmc BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia
    William E Pierceall
    Corresponding Authors Michael Andreeff, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX 77054
    Mol Cancer Ther 12:2940-9. 2013
    ..Taken together, these results highlight the potential utility of BH3 profiling in personalized diagnostics of AML by offering actionable information for patient management decisions...
  40. pmc A general class of semiparametric transformation frailty models for nonproportional hazards survival data
    Sangbum Choi
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biometrics 68:1126-35. 2012
    ..Simulation studies demonstrate that the proposed inference procedures perform well in realistic settings. Applications to two medical studies are provided...
  41. ncbi request reprint Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes
    Janice N Cormier
    Sarcoma Center and Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 22:4567-74. 2004
    ..The role of chemotherapy for these patients remains controversial despite several randomized trials and a meta-analysis...
  42. ncbi request reprint Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1816-9. 2008
    ..004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770...
  43. pmc ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
    Jo Ishizawa
    Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Sci Signal 9:ra17. 2016
    ..Thus, our results suggest that by inducing an atypical ISR and p53-independent apoptosis, ONC201 has clinical potential in hematological malignancies. ..
  44. pmc Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy
    Alfonso Quintas-Cardama
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 14:327-334.e8. 2014
    ..These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum...
  45. pmc A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer
    Sheng Luo
    Division of Biostatistics, University of Texas School of Public Health, 1200 Pressler St, Houston, Texas 77030, USA
    Stat Med 32:2320-34. 2013
    ..Moreover, our method provides useful subject-specific patient prognostic information. Our method is motivated by, and applied to, a dataset of 397 breast cancer patients...
  46. pmc Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:173-80. 2012
    ..These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy...
  47. pmc p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12
    Kensuke Kojima
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 118:4431-9. 2011
    ..This is the first report of Nutlin effect on the bone marrow environment. We suggest that combinations of HDM2 antagonists and FLT3 inhibitors may be effective in clinical trials targeting mutant FLT3 leukemias...
  48. pmc A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Stat Med 30:1218-29. 2011
    ..We illustrate the proposed design through its application to a phase II leukemia clinical trial, and evaluate its operating characteristics through simulation studies...
  49. pmc Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
    Jo Ishizawa
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 10:e0138377. 2015
    ....
  50. pmc Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Sci Transl Med 8:355ra117. 2016
    ....
  51. pmc A two-stage approach for dynamic prediction of time-to-event distributions
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, 77230, TX, U S A
    Stat Med 35:2167-82. 2016
    ..At any time following their treatment with tyrosine kinase inhibitors, longitudinally measured BCR-ABL gene expression levels are used to predict the risk of disease progression. Copyright © 2016 John Wiley & Sons, Ltd. ..
  52. pmc Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
    Jan A Burger
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 15:1090-9. 2014
    ..We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL...
  53. pmc Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma
    Surena F Matin
    Department of Urology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    BJU Int 111:1068-74. 2013
    ..The study shows that robotic inguinal lymphadenectomy allowed adequate staging of disease in the inguinal region by removing all relevant lymph nodes as assessed by an independent evaluating urological oncologist...
  54. ncbi request reprint Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial
    Yu Shen
    Department of Biostatistics and Applied Mathematics, MD Anderson Cancer Center, University of Texas, Houston, 77030, USA
    Biometrics 61:992-9. 2005
    ..We illustrate the methodology using data from a randomized breast cancer screening trial...
  55. pmc CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
    Mariela Sivina
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Blood 117:1662-9. 2011
    ..Collectively, CCL3 is a novel, robust, and independent prognostic marker in CLL that can easily and reliably be measured by ELISA. CCL3 therefore should become useful for risk assessment in patients with CLL...
  56. ncbi request reprint Building and validating a prognostic index for biomarker studies
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biomark 2:97-101. 2006
    ..The prognostic index gets its power from combining prognostic biomarkers. It can be very powerful even when there are few markers that are predictive...
  57. pmc CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
    Koichi Takahashi
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 171:726-35. 2015
    ..These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL. ..
  58. pmc Optimization of multi-stage dynamic treatment regimes utilizing accumulated data
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, U S A
    Stat Med 34:3424-43. 2015
    ..It is applied to identify optimal treatment regimes in a study for advanced prostate cancer and to estimate and compare the final mean rewards of all the possible discrete two-stage treatment sequences...
  59. pmc Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
    Marina Y Konopleva
    Authors Affiliations Department of Leukemia Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Division of Hematology Department of Medicine Department of Epidemiology, University of Washington, Seattle, Washington and National Cancer Institute, Rockville, Maryland
    Clin Cancer Res 20:2226-35. 2014
    ..Subsequently, we conducted a phase II trial of MK-2206 (200 mg weekly) in adults requiring second salvage therapy for relapsed/refractory AML, and assessed target inhibition via reverse phase protein array (RPPA)...
  60. pmc Response-adaptive randomization for clinical trials with adjustment for covariate imbalance
    Jing Ning
    Division of Biostatistics, School of Public Health, The University of Texas, Houston, TX 77030, USA
    Stat Med 29:1761-8. 2010
    ..On the other hand, the proposed design improves over the standard response-adaptive design by controlling covariate imbalance between treatment arms, maintaining the nominal type I error rate, and offering greater power...
  61. ncbi request reprint Metastatic melanoma to lymph nodes in patients with unknown primary sites
    Janice N Cormier
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2012-20. 2006
    ..The natural history of metastatic melanoma in lymph nodes in the absence of a known primary site (MUP) has been defined poorly; thus, treatment guidelines for patients with MUP are not clear-cut...
  62. ncbi request reprint Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
    Sergej Konoplev
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1152-6. 2007
    ..The prognostic significance of CXCR4 expression in patients with AML that have a normal karyotype and no evidence of FLT3 gene mutations was examined...
  63. doi request reprint Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
    Koichi Takahashi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Lancet Oncol . 2016
    ..We aimed to identify whether patients with cancer who have clonal haemopoiesis are at an increased risk of developing therapy-related myeloid neoplasms...
  64. doi request reprint Maximum likelihood estimation of semiparametric mixture component models for competing risks data
    Sangbum Choi
    Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas, Health Science Center at Houston, Houston, Texas 77030, U S A
    Biometrics 70:588-98. 2014
    ..We establish the consistency and asymptotic normality of the proposed estimators. We validate small sample properties with simulations and demonstrate the methodology with a data set from a study of follicular lymphoma...
  65. pmc A class of semiparametric transformation models for survival data with a cured proportion
    Sangbum Choi
    Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1411, Houston, TX, 77030, USA
    Lifetime Data Anal 20:369-86. 2014
    ..Simulation studies are presented to demonstrate the finite sample properties of the proposed method. A case study of stage III soft-tissue sarcoma is given as an illustration. ..
  66. pmc Optimization of individualized dynamic treatment regimes for recurrent diseases
    Xuelin Huang
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, U S A
    Stat Med 33:2363-78. 2014
    ..We illustrate the application of this method using data from a study of acute myeloid leukemia, for which the optimal treatment strategies for different patient subgroups are identified...
  67. ncbi request reprint Eradication of minimal residual disease in hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:4658-62. 2006
    ..Disease characteristics may potentially be used to identify patients that are more likely to benefit from such additional therapy...
  68. ncbi request reprint Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma
    Kong Chao Chang
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Pathol 201:404-12. 2003
    ..The pattern of FDC antigen loss in stroma of FL is a readily assessable biological feature that appears independent of architectural growth pattern and may serve as a useful surrogate marker of tumour progression...
  69. ncbi request reprint Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
    Masamitsu Yanada
    Br J Haematol 138:555-7. 2007
  70. ncbi request reprint Personalized targeted mailing increases mammography among long-term noncompliant medicare beneficiaries: a randomized trial
    R Van Harrison
    Department of Medical Education, University of Michigan, Ann Arbor 48109, USA
    Med Care 41:375-85. 2003
    ....
  71. ncbi request reprint 5-Year mammography rates and associated factors for older women
    R Van Harrison
    Department of Medical Education, University of Michigan, Ann Arbor 48109 0201, USA
    Cancer 97:1147-55. 2003
    ..The current study examined mammography utilization by older women during this period. Relation between mammography utilization and demographic measures and health care-related factors also were examined...
  72. ncbi request reprint Characteristics of primary care physicians and their practices associated with mammography rates for older women
    R Van Harrison
    Department of Medical Education, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer 98:1811-21. 2003
    ..Understanding the relation between the characteristics of primary care physicians (PCPs) and mammography rates for older women can help to target screening improvement efforts...
  73. ncbi request reprint The use of Gaussian quadrature for estimation in frailty proportional hazards models
    Lei Liu
    Division of Biostatistics and Epidemiology, Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908 0717, USA
    Stat Med 27:2665-83. 2008
    ..The proposed method greatly simplifies the implementation of the (joint) frailty models and makes them much more accessible to general statistical practitioners...